Akebia Therapeutics, Inc. (AKBA), Trading M&A For An IPO—Becoming A Huge Contender In Anemia Drug Race
6/9/2014 6:54:03 AM
Akebia Therapeutics and its investors had hit a crossroads familiar to many startup biotechs last year. Its lead drug, AKB-6548, a pill for the anemia people get when their kidneys are failing, had just produced good enough data to move it into a Phase 2b study. If that went well too, the company would need to do a pricey late-stage trial if the drug were to have a chance to make it to market. So more money was needed—a lot of it. Meanwhile, rival drugs, some further along in development, were advancing.
Help employers find you! Check out all the jobs and post your resume.
comments powered by